IDM, Sanofi-Synthélabo Enter Deal Potentially Worth $545M
By James Etheridge
Wednesday, January 23, 2002
PARIS Immuno-Designed Molecules SA, a Paris-based company specialized in the development of cellular immunotherapies for cancer, signed a co-development agreement with the French pharmaceutical company Sanofi-Synthélabo SA covering the whole range of IDMs cell drugs for cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.